The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.
 
Paolo Bossi
Honoraria - MSD Oncology; Prostrakan; Roche
Consulting or Advisory Role - Helsinn Therapeutics; Merck Serono; Mundipharma; Onxeo
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Helsinn Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Rosalba Miceli
No Relationships to Disclose
 
Marco Benasso
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Roche
 
Renzo Corvò
No Relationships to Disclose
 
Almalina Bacigalupo
No Relationships to Disclose
 
Giuseppe Sanguineti
No Relationships to Disclose
 
Carlo Fallai
No Relationships to Disclose
 
Marco Carlo Merlano
Honoraria - Merck Serono; MSD
Consulting or Advisory Role - Merck Serono; MSD
Speakers' Bureau - Merck Serono
 
Gabriele Infante
No Relationships to Disclose
 
Carla Dani
No Relationships to Disclose
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Debiopharm Group; Eisai; GlaxoSmithKline; Merck Serono; MSD; Novartis; SOBI; VentiRx
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Celgene; Debiopharm Group; Merck Serono; MSD; sobi